Group characteristics at inclusion for 7–16 year old children with asthma treated with omeprazole or placebo for GORD
| Omeprazole (n = 19) | Placebo (n = 19) | |
|---|---|---|
| *PAQLQ, Pediatric Asthma Quality of Life Questionnaire. | ||
| †GINA, Global Initiative on Asthma.23 | ||
| Age: mean (median) | 10.2 (9.2) | 11.3 (11.0) |
| Gender (male/female) | 15/4 | 14/5 |
| Reflux index, mean (%, SD) | 8.8 (4.0) | 9.7 (5.1) |
| Not completed (n) | 1 | 1 |
| Patients with reflux index >10% (n) | 5 | 6 |
| Atopic/non-atopic individuals | 13/6 | 13/6 |
| Asthma symptom score: mean (SD) | 5.53 (3.26) | 5.95 (2.92) |
| PAQLQ*: mean (SD) | 5.49 (0.79) | 5.32 (0.95) |
| GINA classification of asthma severity (step 1/2/3/4)† | 4/8/7/0 | 3/6/10/0 |
| Use of short acting bronchodilators (doses past two weeks): mean (SD) | 11.00 (17.23) | 8.28 (8.52) |
| Patients on daily inhaled steroids (n) | 17 | 17 |
| Patients on daily long acting bronchodilators (n) | 10 | 12 |
| FEV1%: mean (SD) | 88.6 (9.5) | 86.9 (7.8) |